Hong Kong, 07 May 2026—Sino Biopharm (SBP Group, 01177) filed a Next Day Disclosure Return confirming no change in its issued share capital while continuing its share-buyback programme.

Issued Share Capital • Outstanding ordinary shares remained at 18.75 billion as at 07 May 2026. • The company held no treasury shares.

Latest On-Market Repurchase • On 07 May 2026, SBP Group bought back 1.85 million shares on the Hong Kong Stock Exchange at prices between HKD 5.39 and HKD 5.46, spending HKD 10.05 million. • These shares are scheduled for cancellation.

Buybacks Pending Cancellation • Between 21 April and 07 May 2026, SBP Group repurchased 23.56 million shares that have yet to be cancelled, equivalent to roughly 0.13 % of the current share base.

Progress Under 2025 Mandate • The June 2025 shareholder mandate authorises repurchases of up to 1.88 billion shares. • To date, 38.91 million shares have been repurchased under the mandate, representing 0.21 % of the issued shares on the mandate date. • A moratorium on new share issues or treasury-share sales is in place until 06 June 2026, in line with Hong Kong listing rules.

The company stated that all repurchases were executed in compliance with the applicable Main Board rules, and no amendments have been made to the previously filed explanatory statement.